Biosimilar Development News

  1. President Trump Can Look To Biosimilars To Keep Promise Of Saving Americans Billions In Health Care Costs 2/4/2020
  2. FDA And FTC Announce New Efforts To Further Deter Anti-Competitive Business Practices, Support Competitive Market For Biological Products To Help Americans 2/3/2020

    The U.S. Food and Drug Administration and the Federal Trade Commission today signed a joint statement regarding enhanced collaboration in support of a robust marketplace for biological products, including the critical adoption of biosimilars and interchangeable products.

  3. Market Analysis: U.S. Biosimilars Market On The Rise 1/31/2020

    The U.S. Biosimilars Market will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, "Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026," The U.S. Biosimilars Market is projected to reach US$ 17,696.0M by 2026. The report provides valuable insights into the drivers influencing growth of the market.

  4. The Competition Council Sanctioned Roche Romania With Fines Of 12,8 Million Euro 1/29/2020

    The Competition Council sanctioned the pharmaceutical company Roche Romania SRL with fines totalling lei 59,967,944 lei (Euro 12,857,897) for abuse of dominant position on the market of oncological products in Romania. The sanctions were applied following two investigations opened in 2017.

  5. Pfizer Brings Three New Biosimilars To U.S. Patients At Substantial Discounts 1/23/2020

    Pfizer announced that it is introducing three new biosimilars, ZIRABEV (bevacizumab-bvzr), RUXIENCE (rituximab-pvvr) and TRAZIMERA (trastuzumab-qyyp) in the United States (U.S.).

  6. Key Trends That Will Shaped The Immunology Market In The Last Decade, According To GlobalData 1/22/2020

    From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.

  7. BioPlan Associates Notes Another Record Year For Drug Approvals From U.S. FDA; 35 Approvals In 2019 1/22/2020

    The US Food and Drug Administration (FDA) set an all-time record, again, for new drug approvals in 2019 with BioPlan Associates, Inc., reporting 35 biopharmaceuticals receiving full (vs. supplemental) approvals in 2019 by the agency's Center for Drug Evaluation and Research (CDER).

  8. Alvotech And JAMP Pharma Enter Into An Exclusive Partnership For The Commercialization Of Key Biosimilars In Canada 1/14/2020

    Our sister company Alvotech and JAMP Pharma have entered into an agreement for an exclusive partnership to supply and commercialize five leading biosimilar candidates in the Canadian market. The current market value of the branded sales for these biosimilars is estimated to exceed $2B annually.

  9. JAMP Pharma Group Signs A Landmark Partnership Agreement For The Commercialization Of Five Biosimilar Medicines In Canada 1/14/2020

    Canadian pharmaceutical company JAMP Pharma Group has signed an exclusive agreement with global speciality biopharmaceutical company Alvotech for the Canadian commercial rights to five biosimilars.

  10. Coherus Acquires Commercial Rights For Avastin® Biosimilar In The United States 1/13/2020

    Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the Company has entered into a licensing agreement with Innovent Biologics, (Suzhou) Co., Ltd., (“Innovent”), a leading biopharmaceutical company headquartered in China, to commercialize Innovent’s biosimilar candidate to Avastin® (bevacizumab) in the United States and Canada.